GetTopicDetailResponse(id=d3511692641, topicName=surufatinib, introduction=surufatinib, content=null, image=null, comments=3, allHits=939, url=https://h5.medsci.cn/topic?id=16926, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=95185, tagList=[TagDto(tagId=95185, tagName=surufatinib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1952264, encodeId=74cf195226423, content=<a href='/topic/show?id=d3511692641' target=_blank style='color:#2F92EE;'>#surufatinib#</a>, objectTitle=Chi-Med公司開始向美國(guó)FDA遞交Surufatinib治療晚期神經(jīng)內(nèi)分泌腫瘤的申請(qǐng), objectType=article, longId=204981, objectId=5ad92049818f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ad92049818f, replyNumber=0, likeNumber=81, createdTime=2021-05-21, rootId=0, userName=chentianping, userId=f634250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ad92049818f, moduleTitle=Chi-Med公司開始向美國(guó)FDA遞交Surufatinib治療晚期神經(jīng)內(nèi)分泌腫瘤的申請(qǐng), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5ad92049818f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952263, encodeId=c163195226353, content=<a href='/topic/show?id=d3511692641' target=_blank style='color:#2F92EE;'>#surufatinib#</a>, objectTitle=晚期神經(jīng)內(nèi)分泌腫瘤的治療或迎新進(jìn)展！和記黃埔已向EMA提交Surufatinib的營(yíng)銷授權(quán)申請(qǐng), objectType=article, longId=199177, objectId=3bc11991e7f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bc11991e7f6, replyNumber=0, likeNumber=69, createdTime=2021-03-26, rootId=0, userName=chentianping, userId=f634250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bc11991e7f6, moduleTitle=晚期神經(jīng)內(nèi)分泌腫瘤的治療或迎新進(jìn)展！和記黃埔已向EMA提交Surufatinib的營(yíng)銷授權(quán)申請(qǐng), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3bc11991e7f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952262, encodeId=de7319522628b, content=<a href='/topic/show?id=d3511692641' target=_blank style='color:#2F92EE;'>#surufatinib#</a>, objectTitle=和記黃埔的Surufatinib獲得FDA授予快速通道指定，用于治療胰腺和非胰腺神經(jīng)內(nèi)分泌腫瘤, objectType=article, longId=192484, objectId=fb0c19248469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb0c19248469, replyNumber=0, likeNumber=88, createdTime=2021-02-20, rootId=0, userName=chentianping, userId=f634250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb0c19248469, moduleTitle=和記黃埔的Surufatinib獲得FDA授予快速通道指定，用于治療胰腺和非胰腺神經(jīng)內(nèi)分泌腫瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fb0c19248469)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
